---
schema_version: "secwatch.filing_event.v1"
accession: "0001651308-23-000066"
form_type: "8-K"
ticker: "ONC"
cik: "0001651308"
company_name: "BeOne Medicines Ltd."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:15:10.483660+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BeiGene Q1 product revenue $410.3M (+57% YoY); BRUKINSA sales double to $211.4M

## Summary
- Net loss narrowed to $348.4M ($0.26 per share) from $435.2M a year ago; operating leverage improved.
- Global BRUKINSA sales of $211.4M, up 103% YoY, driven by U.S. CLL/SLL launch ($138.8M U.S.).
- Tislelizumab revenue in China $114.9M (+31% YoY); 10 approved indications in China.
- Cash and short-term investments $3.8B as of March 31, 2023; operating cash outflow $563.8M in Q1.
- R&D expenses $408.6M; SG&A $328.5M; gross margin improved to 80.1% from 75.1%.

## SEC filing metadata
- accession: 0001651308-23-000066
- form_type: 8-K
- ticker: ONC
- cik: 0001651308
- company_name: BeOne Medicines Ltd.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/0001651308-23-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/bgne-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001651308-23-000066
- JSON: https://secwatch.observer/filing/0001651308-23-000066.json
- Plain text: https://secwatch.observer/filing/0001651308-23-000066.txt

## Key facts
- Earnings Releases
  BeOne Medicines Ltd. reported the three months ended March 31, 2023 results: revenue $447.8 million, net income $348.4 million, EPS $0.26 per share.
  - Period: the three months ended March 31, 2023
  - Revenue: $447.8 million
  - Net income: $348.4 million
  - EPS: $0.26 per share
  - Result: reported results
  source text: faster than operational expenses, BeiGene is well positioned for future growth.” First Quarter 2023 Financial Results Revenue for the three months ended March 31, 2023, was $447.8 million, compared to $306.6 million in the same period of 2022. • Product revenue totaled $410.3 million for the three months ended March 31, 2023, compared to $261.6 million in the same
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651308/000165130823000066/0001651308-23-000066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.